871123-98-7

Basic information

• Product Name: (2S,3S)-2-Amino-3-benzylsuccinic ammonium salt, DL-TBOA
• Synonyms: (2S,3S)-2-Amino-3-benzylsuccinic ammonium salt, DL-TBOA;L-β-threo-benzyl-aspartate ammonium salt;(2S,3S)-2-Amino-3-benzylsuccinic acid;L-β-threo-benzyl-aspartate;(3S)-3-(Phenylmethyl)-L-aspartic acid
• CAS NO: 871123-98-7
• Molecular Formula: C11H13NO4
• Molecular Weight: 223.23
• Mol File: 871123-98-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (2S,3S)-2-Amino-3-benzylsuccinic ammonium salt, DL-TBOA(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3S)-2-Amino-3-benzylsuccinic ammonium salt, DL-TBOA(871123-98-7)
• EPA Substance Registry System: (2S,3S)-2-Amino-3-benzylsuccinic ammonium salt, DL-TBOA(871123-98-7)

Safety Data

• Hazardous Substances Data: 871123-98-7(Hazardous Substances Data)

Usage

General Description

The compound (2S,3S)-2-Amino-3-benzylsuccinic ammonium salt, DL-TBOA is a chemical compound that acts as a selective inhibitor of excitatory amino acid transporters (EAATs). It is commonly used in research to study the function of EAATs and their role in synaptic transmission. The compound has potential applications in the treatment of neurological disorders, as EAATs are involved in the regulation of glutamate levels in the brain, which is a key neurotransmitter involved in various neurological processes. The compound is also being investigated for its potential use as a therapeutic agent for conditions such as epilepsy and ischemia.

Upstream product

• 885357-46-0 dimethyl N-tritylamino-β-benzylaspartate 
• 99477-50-6 2-Amino-3-benzyl-succinic acid 

Relevant articles and documents

Structure-guided engineering of: Pseudomonas dacunhae l-aspartate β-decarboxylase for l-homophenylalanine synthesis

Structure-guided engineering of Pseudomonas dacunhael-aspartate β-decarboxylase (AspBDC) resulted in a double mutant (R37A/T382G) with remarkable 15400-fold improvement in specific activity reaching 216 mU mg-1, towards the target substrate 3(R)-benzyl-l-aspartate. A novel strategy for enzymatic synthesis of l-homophenylalanine was developed by using the variant as a biocatalyst affording 75% product yield within 12 h. Our results underscore the potential of engineered AspBDC for the biocatalytic synthesis of pharmaceutically relevant and value added unnatural l-amino acids.

3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission

The present invention provides an L-aspartate derivative compound represented by the following structure wherein Ar represents an aromatic group; L represents a linking moiety; R represents hydrogen, alkyl, aryl, or heteroaryl; and indicates that the stereochemistry at the 3-position can be R or S. The compounds of the invention are useful for selectively inhibiting EAAT3 and for enhancing synaptic transmission. Additionally, the inventive compounds can be used to treat a patient suffering from Alzheimers disease or a neuropathy or a neurodegenerative disease in which L-glutamate transporter activity is involved in the onset of the disease.